Selinexor

Selinexor (generic name: KPT-330) is a novel, orally-available selective inhibitor of nuclear export (SINE) that blocks the export of tumor suppressor proteins out of the nucleus. This can lead to increased apoptosis (programmed cell death) and tumor regression. Selinexor is currently being studied in a variety of solid tumors, including multiple myeloma and metastatic prostate cancer, and has been granted fast-track and breakthrough therapy designations from the FDA.

Selexipag focuses on pulmonary arterial hypertension, whereas Selinexor targets different conditions. Here's a breakdown of Selinexor:

Selinexor (XPOVIO® or NEXPOVIO®):

• Type: Selective inhibitor of nuclear export (SINE) compound [1].
• Conditions Treated:
  • Approved for:
    • Multiple myeloma (a cancer of plasma cells in bone marrow) [1, 2].
  • Investigational use (ongoing studies for):
    • Endometrial cancer (cancer of the lining of the uterus) [3]
    • Myelodysplastic syndromes (MDS, a group of bone marrow disorders) [4]
    • Myelofibrosis (a bone marrow disorder) [5]

How it Works:

• Selinexor works by blocking the activity of a protein called Exportin 1 (XPO1) [1]. XPO1 is involved in transporting various molecules out of the cell nucleus.
• By inhibiting XPO1, Selinexor traps tumor suppressor proteins inside the cell nucleus, where they can exert their anti-cancer effects [2].

Dosage and Administration:

• Selinexor comes as capsules taken orally, typically once a week on an empty stomach [1].
• The exact dosage is determined by factors like a patient's weight, body surface area, and overall health.

Benefits:

• In multiple myeloma, Selinexor can help induce remission (reduction or disappearance of cancer cells) and improve progression-free survival (time without the disease worsening) [2].

Side Effects:

• Common side effects of Selinexor can include [1, 2]:
  • Fatigue
  • Nausea
  • Vomiting
  • Decreased appetite
  • Electrolyte imbalances (low blood sodium, potassium, or magnesium)
  • Thrombocytopenia (low blood platelet count)
• Serious side effects can occur, and it's crucial to report any concerning symptoms to your doctor promptly.

Important Considerations:

• Selinexor is only available through a restricted distribution program due to potential side effects [1].
• It's not suitable for everyone and can interact with other medications. It's essential to disclose your full medical history to your doctor before starting Selinexor.
• Women who are pregnant or breastfeeding should not take Selinexor due to potential risks to the developing baby [1].

If you have multiple myeloma or any of the conditions for which Selinexor is being investigated, talk to your doctor about whether it might be a suitable treatment option for you. They can assess your individual situation and potential benefits and risks.

Here are some additional points to note:

• Selinexor is a relatively new medication, and long-term studies are ongoing to evaluate its efficacy and safety in various conditions [2, 3, 4, 5].
• There are other treatment options available for multiple myeloma and other cancers, and your doctor will recommend the best approach based on your specific case.